<DOC>
	<DOCNO>NCT02832180</DOCNO>
	<brief_summary>This open-label , 2-cycle , multiple-dose , single-sequence study woman child-bearing potential . The primary objective ass effect BMS-986142 pharmacokinetics ( PK ) Combined Oral Contraceptive Containing Ethinyl Estradiol Norethindrone Acetate .</brief_summary>
	<brief_title>The Effect BMS-986142 Pharmacokinetics Combined Oral Contraceptive ( OC ) Containing Ethinyl Estradiol ( EE ) Norethindrone Acetate ( NET ) Healthy Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norinyl</mesh_term>
	<mesh_term>Norethindrone acetate , ethinyl estradiol , ferrous fumarate drug combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Signed Informed Consent Target population : Healthy female clinically significant deviation normal medical history , physical examination , vital sign , electrocardiogram ( ECGs ) , physical measurement , clinical laboratory test willing switch Loestrin study . Body Mass Index ( BMI ) 18 32 kg/m2 . Women childbearing potential intact ovarian function history regular menstrual cycle must stable regimen combination birth control contain ethinyl estradiol without evidence clinically significant breakthrough bleed spot least 2 consecutive month prior Day 1 . Women childbearing potential must agree follow instruction method ( ) contraception duration treatment study drug ( 53 day ) plus 5 halflives BMS986142 ( 3 day ) plus 30 day ( duration ovulatory cycle ) total 86 day . History chronic acute illness include active TB last 3 year , recent infection , gastrointestinal disease , smoke within less 6 month prior dose , alcohol abuse , inability tolerate oral medication , inability venipunctured . History jaundice irregular bleeding associate take oral contraceptive , frequent headache , cerebrovascular coronaryartery disease , retinal vascular lesion , cancer breast endometrium , deep venous thrombosis , pulmonary embolism , stroke , transient ischemic attack , phlebitis . Vaccination plan vaccination live vaccine 12 week prior first dose study drug , course study , 30 day last dose study drug . Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , electrocardiogram , clinical laboratory determination beyond consistent target population . History allergy adverse drug reaction oral contraceptive compound Bruton tyrosine kinase ( BTK ) inhibitor .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Rheumatoid</keyword>
</DOC>